Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

This study uses a blood test that detects tiny fragments of tumor DNA (called molecular residual disease, or MRD) to decide whether patients with high-risk kidney cancer (renal cell carcinoma) who had surgery should receive follow-up immunotherapy treatment. **You may be eligible if:** - You are 18 or older - You have high-risk or intermediate-high-risk kidney cancer (clear cell type) - You recently had your kidney (partially or fully) removed - You have had an MRD blood test (Signatera) within the past 90 days - You have not received prior systemic therapy for kidney cancer (or only just started pembrolizumab) **You may NOT be eligible if:** - You are on immune-suppressing medications or have an autoimmune disease requiring treatment - You have had an organ transplant - You have HIV, active hepatitis B/C, or active tuberculosis - You are pregnant or breastfeeding - You received a live vaccine in the past 30 days Talk to your doctor to see if this trial is right for you.